Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Horizon Therapeutics Public Limited Company HZNP NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - General • IE • USD

SharesGrow Score
68/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$127.15
+9.3%

Horizon Therapeutics Public Limited Company (HZNP) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $116.30. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is HZNP = $127 (+9.3% upside).

Financials: revenue is $3.6B, +42.8%/yr average growth. Net income is $521M, growing at +0.9%/yr. Net profit margin is 14.4% (healthy). Gross margin is 74.6% (+2.5 pp trend).

Balance sheet: total debt is $2.6B against $5.1B equity (Debt-to-Equity (D/E) ratio 0.51, moderate). Current ratio is 3.85 (strong liquidity). Debt-to-assets is 28.1%. Total assets: $9.1B.

Analyst outlook: 15 / 25 analysts rate HZNP as buy (60%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 40/100 (Partial), Growth 73/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 80/100 (Pass), Future 61/100 (Pass), Income 55/100 (Partial).

$127.15
▲ 9.33% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Horizon Therapeutics Public Limited Company, the average price target is $127.15, with a high forecast of $144.00, and a low forecast of $110.00.
Highest Price Target
$144.00
Average Price Target
$127.15
Lowest Price Target
$110.00

HZNP SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 40/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 80/100
Gross margin is + market cap
FUTURE 61/100
Analyst outlook — as buy
INCOME 55/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HZNP

~
VALUE Partial
40/100
HZNP trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $127, implying +9.2% from the current price $116. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
73/100
HZNP: +42.8%/yr revenue is, +0.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
HZNP: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet HZNP: Debt-to-Equity (D/E) ratio 0.51 (moderate), Current ratio is 3.85 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
80/100
HZNP: Gross margin is 74.6% (+2.5 pp trend), $27B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 80/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
61/100
Analyst outlook: 15 / 25 analysts rate HZNP as buy (60%). Analyst consensus target is $127 (+9.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
~
INCOME Partial
55/100
HZNP: Net profit margin is 14.4%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range116.3-116.34
Volume23.92M
Avg Volume (30D)23.92M
Market Cap$26.6B
Beta (1Y)1.01
Share Statistics
EPS (TTM)2.28
Shares Outstanding$229.11M
IPO Date2011-07-28
Employees2,190
CEOTimothy P. Walbert
Financial Highlights & Ratios
Revenue (TTM)$3.63B
Gross Profit$2.71B
EBITDA$1.11B
Net Income$521.48M
Operating Income$617.41M
Total Cash$2.35B
Total Debt$2.56B
Net Debt$210M
Total Assets$9.11B
Price / Earnings (P/E)51
Price / Sales (P/S)7.33
Analyst Forecast
1Y Price Target$126.50
Target High$144.00
Target Low$110.00
Upside+8.8%
Rating ConsensusBuy
Analysts Covering25
Buy 60% Hold 40% Sell 0%
Company Info
CountryIE
ExchangeNASDAQ Global Select
CurrencyUSD
ISINIE00BQPVQZ61

Price Chart

Track all markets on TradingView
HZNP
Horizon Therapeutics Public Limited Company ↗  ·  NASDAQ Global Select
Healthcare • Drug Manufacturers - General
116.30 52WK RANGE 116.34

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
 NVS
NVS
Novartis AG
$153.38
-0.71%
 AMGN
AMGN
Amgen Inc.
$350.95
+0.32%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message